We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Januvia

News List

Unichem Labs gets tentative US FDA approval for Sitagliptin Tablets USP expresspharma
July 12, 2021
Sitagliptin tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Merck files petition in US court against Aurobindo Pharma for Janumet expresspharma
August 27, 2020
In June, Merck had filed a petition against Dr Reddy's Laboratories in a US court over similar patent issues on Janumet and Januvia.
Novo Nordisk trumpets more Januvia-topping data for oral semaglutide fiercepharma
July 02, 2018
Just eight days after posting a trial win over Merck diabetes stalwart Januvia, Novo Nordisk candidate semaglutide is back with another.
Novo Nordisk's oral semaglutide impresses analysts against Victoza, Januvia fiercepharma
June 25, 2018
Once it wins approval, Novo Nordisk’s highly anticipated oral diabetes drug semaglutide will go up against some stiff competition. But the drugmaker just showed that its up-and-comer can take the heat.
Novo's oral semaglutide beats Victoza and Januvia in diabetes pharmafile
June 22, 2018
Novo Nordisk has released new data for its oral semaglutide diabetes therapy from two trials, showing that the GLP-1 analogue was more effective in reducing HbA1c and weight in patients compared to MSD’s Januvia (sitagliptin) and its own best-selling inje